This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
Gilead signs hepatitis C drug (sofosbuvir – SOVALDI and ledipasvir) pact to make treatment available in low income countries
(Reuters, Sept. 15, 2014)
“U.S. drugmaker Gilead Sciences Inc GILD.O has licensed its hepatitis C drug Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the $1,000-a-pill medicine in 91 developing nations…Gilead said it would also launch its own branded Sovaldi in India at a price of $300 a month. The drug is normally given for either three or six months and costs $84,000 for a 12-week course in the United States. Gilead’s next-generation version is going to be even more expensive.”
————————————————-
Interesting responses to above article:
KEI (Knowledge Ecology International) welcomes the Gilead HCV licenses, as a step to expand access to treatments. Notes challenges that remain
http://keionline.org/node/2082
————————————————–
Also see:
